Esperion Therapeutics
Michael LaButis has a diverse work experience that spans over 15 years. Michael is currently the Director of Financial Planning and Analysis at Esperion since 2023. Prior to that, they held various finance roles at Bristol Myers Squibb, including Finance Director of U.S. Hematology - Myeloid and Finance Associate Director of U.S. Oncology. Michael also worked as a Finance Manager in the U.S. Oncology division and as a Supervisor in Audit Services. Before joining Bristol Myers Squibb, Michael worked as an Audit Supervisor at KPMG Netherlands and as an Audit Senior at KPMG LLP. Their work mainly involved financial planning and analysis, financial reporting, audit services, and team supervision.
Michael LaButis has obtained a Bachelor of Science degree in Accounting from The Pennsylvania State University. The exact duration of their education, including the start and end years, is not specified.
This person is not in any offices
Esperion Therapeutics
2 followers
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at ESPERION is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.